We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
Impurities in Peptide Drug Substance and Challenges Faced during Registration (in US, EU, Brazil and China Markets) and Commercial Phase
20 Mar 2025 - Controlling impurities in complex drug substances is a crucial part of development and due to lack of harmonized approaches from Health authorities, the manufacturer faces many […]
Read morePolyPeptide publishes invitation to the annual General Meeting 2025
18 Mar 2025 - Baar, 18 March 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fourth […]
Read morePolyPeptide with substantial improvements in profitability and cash flow, positioned for strong growth
11 Mar 2025 - Baar, 11 March 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its annual results for 2024 […]
Read moreCytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs
13 Jan 2025 - This collaboration offers an integrated solution for customers seeking to outsource the development and manufacturing of microbial and mammalian-expressed peptide drugs, with scalable options that address […]
Read moreDoubling of production capacity at the manufacturing site in Malmö
8 Jan 2025 - Baar, 8 January 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the planned doubling of solid-phase peptide […]
Read moreLarge-scale SPPS capacity in Braine-l’Alleud starts production
16 Dec 2024 - Baar, 16 December 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the start of production with the […]
Read morePeptide Manufacturing: Rethinking the Technology Platform for Large Scale Demand
13 Nov 2024 - Presented at TIDES Europe, November 13, 2024 Speaker: Jan Pawlas, Scientist Global Development Abstract: The peptide market is strongly impacted by the evolution of the development pipeline, […]
Read moreVinnova grant awarded to joint project between PolyPeptide and Red Glead Discovery for developing a more sustainable manufacturing method for a GLP-1 agonist.
27 Aug 2024 - PolyPeptide in Limhamn, Sweden and Red Glead Discovery in Lund, Sweden have joined forces to pursue the development of a more sustainable manufacturing method for a […]
Read moreSolid progress in H1 2024 – Upgrade of 2024 full-year guidance – Mid-term target to double 2023 revenue by 2028
13 Aug 2024 - Baar, 13 August 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, today announced its results for H1 2024, […]
Read more